Antares Pharma, Inc. (ATRS): Price and Financial Metrics


Antares Pharma, Inc. (ATRS): $5.59

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ATRS POWR Grades


  • ATRS scores best on the Value dimension, with a Value rank ahead of 81.19% of US stocks.
  • ATRS's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • ATRS's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

ATRS Stock Summary

  • Of note is the ratio of Antares Pharma Inc's sales and general administrative expense to its total operating expenses; 99.53% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of -46.25%, Antares Pharma Inc's debt growth rate surpasses only 8.48% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Antares Pharma Inc is reporting a growth rate of 380.61%; that's higher than 94.35% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Antares Pharma Inc are MYOV, MIME, ASTC, FLGT, and CVLT.
  • Visit ATRS's SEC page to see the company's official filings. To visit the company's web site, go to www.antarespharma.com.

ATRS Valuation Summary

  • In comparison to the median Healthcare stock, ATRS's EV/EBIT ratio is 6.83% lower, now standing at 27.3.
  • ATRS's price/sales ratio has moved down 7.8 over the prior 243 months.
  • Over the past 243 months, ATRS's price/sales ratio has gone down 7.8.

Below are key valuation metrics over time for ATRS.

Stock Date P/S P/B P/E EV/EBIT
ATRS 2021-08-31 3.9 5.0 10.3 27.3
ATRS 2021-08-30 3.9 5.1 10.4 27.5
ATRS 2021-08-27 3.9 5.1 10.5 27.7
ATRS 2021-08-26 3.8 4.9 10.0 26.6
ATRS 2021-08-25 3.8 5.0 10.2 27.0
ATRS 2021-08-24 3.9 5.1 10.3 27.4

ATRS Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 154.75%.
  • Its 2 year net income to common stockholders growth rate is now at 106.35%.
  • Its 4 year revenue growth rate is now at 169.31%.
Over the past 70 months, ATRS's revenue has gone up $134,353,165.

The table below shows ATRS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 183.982 36.619 46.289
2021-09-30 179.385 34.23 64.992
2021-06-30 171.197 20.47 64.595
2021-03-31 158.603 17.718 62.35
2020-12-31 149.599 21.32 56.201
2020-09-30 143.305 13.087 9.51

ATRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATRS has a Quality Grade of C, ranking ahead of 47.93% of graded US stocks.
  • ATRS's asset turnover comes in at 0.857 -- ranking 29th of 186 Medical Equipment stocks.
  • VASO, MMSI, and NAOV are the stocks whose asset turnover ratios are most correlated with ATRS.

The table below shows ATRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.857 0.705 0.197
2021-03-31 0.869 0.676 0.173
2020-12-31 0.923 0.639 0.121
2020-09-30 1.009 0.595 0.122
2020-06-30 1.028 0.603 0.090
2020-03-31 1.066 0.592 0.050

ATRS Price Target

For more insight on analysts targets of ATRS, see our ATRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.64 Average Broker Recommendation 1.29 (Strong Buy)

ATRS Stock Price Chart Interactive Chart >

Price chart for ATRS

ATRS Price/Volume Stats

Current price $5.59 52-week high $5.60
Prev. close $5.59 52-week low $3.11
Day low $5.58 Volume 2,707,400
Day high $5.60 Avg. volume 3,291,313
50-day MA $4.86 Dividend yield N/A
200-day MA $3.91 Market Cap 955.06M

Antares Pharma, Inc. (ATRS) Company Bio


Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company was founded in 1979 and is based in Ewing, New Jersey.


ATRS Latest News Stream


Event/Time News Detail
Loading, please wait...

ATRS Latest Social Stream


Loading social stream, please wait...

View Full ATRS Social Stream

Latest ATRS News From Around the Web

Below are the latest news stories about Antares Pharma Inc that investors may wish to consider to help them evaluate ATRS as an investment opportunity.

Antares Pharma (NASDAQ:ATRS) Could Easily Take On More Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | February 18, 2022

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The

Yahoo | February 17, 2022

Henry Schein (HSIC) Q4 Earnings and Revenues Beat Estimates

Henry Schein (HSIC) delivered earnings and revenue surprises of 18.89% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 15, 2022

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®

PDUFA target action date set for March 28, 2022EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”). The FDA designated the NDA as a Class 1 resubmission with a two-month review goal perio

Yahoo | February 3, 2022

Arrow Financial Corp Buys iShares Core MSCI International Developed Markets , PowerShares QQQ ...

Glens Falls, NY, based Investment company Arrow Financial Corp (Current Portfolio) buys iShares Core MSCI International Developed Markets , PowerShares QQQ Trust Ser 1, Caterpillar Inc, Dollar Tree Inc, Activision Blizzard Inc, sells Netflix Inc, iShares iBonds Dec 2021 Term Corporate ETF, Lockheed Martin Corp, Gilead Sciences Inc, Goldman Sachs Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Arrow Financial Corp.

Yahoo | January 28, 2022

Read More 'ATRS' Stories Here

ATRS Price Returns

1-mo 0.36%
3-mo 60.17%
6-mo 69.39%
1-year 37.35%
3-year 94.10%
5-year 122.71%
YTD 56.58%
2021 -10.53%
2020 -15.11%
2019 72.79%
2018 36.68%
2017 -14.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.4833 seconds.